29263-11-4

Usage

General Description

2,4,6-tris(propan-2-yloxy)-1,3,5-triazine, also known as Cyanuric acid tris(2-propanol), is a chemical compound consisting of a triazine ring with three propan-2-yloxy substituents. It is commonly used as a cross-linking agent in the production of polymers, particularly in the manufacturing of resins and coatings. 2,4,6-tris(propan-2-yloxy)-1,3,5-triazine is also utilized as a stabilizer in the formulation of adhesives, plastics, and rubber products to improve their durability and resistance to heat and chemicals. Additionally, 2,4,6-tris(propan-2-yloxy)-1,3,5-triazine is employed as an intermediate in the synthesis of various organic compounds and pharmaceuticals. Despite its usefulness, this chemical should be handled with care due to its potential health hazards and environmental impacts.

Upstream product

• 108-77-0 1,3,5-trichloro-2,4,6-triazine 
• 683-60-3 sodium isopropylate 
• 67-63-0 isopropyl alcohol 

Relevant academic research and scientific papers

Synthesis and antiviral evaluation of some C3-symmetrical trialkoxy-substituted 1,3,5-triazines and their molecular geometry

As one of our projects, we here report some new molecular modifications of 2,4,6-trichloro-1,3,5-triazine (TCTAZ: 1) to symmetrical 2,4,6-trialkoxy- or 2,4,6-triaryloxy-substituted 1,3,5-triazine (TAZ) molecules, as well as the results of anti-herpes simplex virus type 1 (anti-HSV-1) activity evaluation of synthesized 2,4,6-trisubstituted TAZ derivatives. Among the tested 2,4,6-trisubstituted TAZ derivatives, we reconfirmed that a C3-symmetrical TAZ derivative, 4e, shows the highest level of anti-HSV-1 activity with a good selectivity index. In this paper, we also report the results of the preparation of newly targeted TAZ derivatives and the structure-activity relationships (SARs) of these trialkoxy-substituted TAZ derivatives and related compounds. The sugar recognition properties of C3-symmetrical TAZ derivative 4e are also described.

USE OF A L,3J5-TRIAZIN-2-YL PHOSPHORAMIDATE COMPOUND IN THE SYNTHESIS OF SOFOSBUVIR

The present invention relates to a new type of 1,3.5-triazin-2-yl phosphoramidates of general formula I with the absolute configuration (S) at the phosphorus atom, an Sp diastereoisomer, wherein R1 and R2 can independently be H, a C1-C6 (un)branched alkyl, a C1-C6 (un)branched alkoxy group, a C1-C6 (un)branched alkylsulfanyl group, C1-C6 (un)branched monoalkylamino or dialkylamino group, including cyclic amino groups, e.g. pyrrolidino, piperidino or morpholino group; and to their use for the production of biologically active phosphoramidate prodrugs, especially sofosbuvir of formula II. Sofosbuvir II is a nucleotide inhibitor of the RNA polymerase, used for the treatment of hepatitis C in the form of a prodrug, releasing the active antiviral agent 2'-deoxy-2'-a-fluoro- P-C-methyluridine-5'-triphosphate in the organism.